PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
6205124-3	1984	The acute and chronic effects of sodium valproate were also produced by aminooxyacetic acid, an inhibitor of gamma-aminobutyric acid (GABA) transaminase, while another GABA transaminase inhibitor, ethanolamine-O-sulphate, and THIP, a GABA receptor agonist, were effective after acute administration.	Valproic Acid	33-49	4-aminobutyrate aminotransferase	Rattus norvegicus	168-185	
6420629-3	1983	Inhibition of GABA-transaminase (GABA-T) by aminooxyacetic acid (AOAA) in other compartments of the brain would result in an inhibition of the stimulated GABA-release via feedback on autoreceptors and therefore suppress the DPA-evoked behaviour.	Valproic Acid	224-227	4-aminobutyrate aminotransferase	Rattus norvegicus	14-31	
6420629-3	1983	Inhibition of GABA-transaminase (GABA-T) by aminooxyacetic acid (AOAA) in other compartments of the brain would result in an inhibition of the stimulated GABA-release via feedback on autoreceptors and therefore suppress the DPA-evoked behaviour.	Valproic Acid	224-227	4-aminobutyrate aminotransferase	Rattus norvegicus	33-39	
8247350-0	1993	In vivo administration of valproate reduces the nerve terminal (synaptosomal) activity of GABA aminotransferase in discrete brain areas of rats.	Valproic Acid	26-35	4-aminobutyrate aminotransferase	Rattus norvegicus	90-111	
6810779-8	1982	VPA, in high doses (300-400 mg/kg) exerted similar cardiovascular effects in rats as observed with GABA and GABA-T inhibitors.	Valproic Acid	0-3	4-aminobutyrate aminotransferase	Rattus norvegicus	108-114	
20614021-3	2010	Valproate, a widely used antiepileptic drug, has a number of targets including GABA transaminase, voltage-gated sodium channels, glycogen synthase kinase (GSK)-3, and histone deacetylases (HDACs), and therefore may attenuate a number of TBI-associated pathologies.	Valproic Acid	0-9	4-aminobutyrate aminotransferase	Rattus norvegicus	79-96	
11025174-4	2000	4-Hydroxybenzaldehyde, an analogue of p-hydroxybenzyl alcohol, showed an inhibitory effect on the GABA transaminase, and its inhibitory activity was higher than that of valproic acid, a known anticonvulsant.	Valproic Acid	169-182	4-aminobutyrate aminotransferase	Rattus norvegicus	98-115	
9264079-3	1997	The ability of the GABAB agonist baclofen and the GABA transaminase inhibitor sodium valproate to block the enhanced distractibility produced by amphetamine was evaluated in a procedure especially designed for analyzing drugs" effects on distractibility.	Valproic Acid	78-94	4-aminobutyrate aminotransferase	Rattus norvegicus	50-67	
8564234-2	1995	The GABA transaminase inhibitor and activator of glutamic acid decarboxylase, valproic acid is being used for the treatment of migraine.	Valproic Acid	78-91	4-aminobutyrate aminotransferase	Rattus norvegicus	4-21	
1660103-9	1991	The effects of the GABA transaminase inhibitors gamma-acetylene GABA and sodium valproate were similar to those of the receptor agonists.	Valproic Acid	73-89	4-aminobutyrate aminotransferase	Rattus norvegicus	19-36	
2159160-1	1990	It has previously been found that the GABA transaminase inhibitors gamma-acetylen GABA (GAG) and sodium valproate reduced intromission behavior in male rats without affecting mounting behavior.	Valproic Acid	97-113	4-aminobutyrate aminotransferase	Rattus norvegicus	38-55	
6812585-3	1982	Sodium valproate significantly enhanced the activity of GAD in the medulla and pons, cerebellum and midbrain regions of rats, and partially relieved the suppression of GAD activity caused by chronic GABA-transaminase inhibition in whole mouse brain.	Valproic Acid	0-16	4-aminobutyrate aminotransferase	Rattus norvegicus	199-216	
6171410-4	1981	Sodium valproate (VPA, di-n-propylacetic acid), which is also believed to block GABA-transaminase and succinic semialdehyde dehydrogenase, when administered in a dose of 200 mg/kg (i.p.)	Valproic Acid	0-16	4-aminobutyrate aminotransferase	Rattus norvegicus	80-97	
6171410-4	1981	Sodium valproate (VPA, di-n-propylacetic acid), which is also believed to block GABA-transaminase and succinic semialdehyde dehydrogenase, when administered in a dose of 200 mg/kg (i.p.)	Valproic Acid	18-21	4-aminobutyrate aminotransferase	Rattus norvegicus	80-97	
6171410-4	1981	Sodium valproate (VPA, di-n-propylacetic acid), which is also believed to block GABA-transaminase and succinic semialdehyde dehydrogenase, when administered in a dose of 200 mg/kg (i.p.)	Valproic Acid	23-45	4-aminobutyrate aminotransferase	Rattus norvegicus	80-97	
8247350-1	1993	Previous in vitro experiments have indicated that neuronal GABA aminotransferase (GABA-T) differs from extraneuronal GABA-T in sensitivity to certain enzyme inhibitors, including the antiepileptic drug valproate (VPA).	Valproic Acid	202-211	4-aminobutyrate aminotransferase	Rattus norvegicus	59-80	
8247350-1	1993	Previous in vitro experiments have indicated that neuronal GABA aminotransferase (GABA-T) differs from extraneuronal GABA-T in sensitivity to certain enzyme inhibitors, including the antiepileptic drug valproate (VPA).	Valproic Acid	202-211	4-aminobutyrate aminotransferase	Rattus norvegicus	82-88	
8247350-1	1993	Previous in vitro experiments have indicated that neuronal GABA aminotransferase (GABA-T) differs from extraneuronal GABA-T in sensitivity to certain enzyme inhibitors, including the antiepileptic drug valproate (VPA).	Valproic Acid	213-216	4-aminobutyrate aminotransferase	Rattus norvegicus	59-80	
8247350-1	1993	Previous in vitro experiments have indicated that neuronal GABA aminotransferase (GABA-T) differs from extraneuronal GABA-T in sensitivity to certain enzyme inhibitors, including the antiepileptic drug valproate (VPA).	Valproic Acid	213-216	4-aminobutyrate aminotransferase	Rattus norvegicus	82-88